Supporting research in the field of MS remained one of our three pillars after 30 years. With our active involvement in the EU-funded scientific project of Nose-to-Brain-patch (N2B-patch), we enabled the inclusion of patients’ perspectives at an early stage of this scientific project. The new generation of researchers ask the persons affected by any disease about products that the scientists intend to develop for those affected by the disease. In 2019, we did exactly that. We made sure to bring the questions and expertise of MS community to the table, as well as kept our members and wider society informed about the innovative outcome of this multi-stakeholder project.
The N2B-patch project is a European Union’s Horizon 2020 Research and Innovation programme-funded project that has received funding under the grant agreement No. 721098 and started in January 2017. N2B-patch stands for “Nose-to-Brain-patch”. The consortium aims to develop an innovative technology for multiple sclerosis (MS) treatment by developing a ‘nose to brain’ delivery system which will avoid the need for injections and oral medicine. The direct transport route from the nasal cavity to the brain, bypassing the blood-brain barrier, could potentially offer an innovative method for central nervous system drug delivery. The long-term objective is to improve treatment of people with MS. Science, industry and patients’ representatives work hand in hand in order to achieve the project objectives and maximise impact for patients and their relatives, healthcare professionals and European industries.